I
Inyx Inc. Stock Analysis IYXI
Inyx, Inc. is pharmaceutical company, which develops and acquires niche pharmaceutical products and drug delivery systems for key therapeutic areas, including respiratory and dermatological applications. The company is headquartered in New York City, New York and currently employs 572 full-time employees. The company went IPO on 2003-02-19. Its operations are focused on the development of both prescriptions, over the counter pharmaceutical products, and specialty consulting services. Also, the Company utilizes niche drug delivery capabilities to develop its own products. The product and service categories of the Company include Metered Dose Inhalers (MDIs) (CFC & HFA), Dry Powder Inhalers (DPIs), Metered Dose Pump Sprays (nasal and oral), Hydrocarbon Foam Aerosols, Saline Aerosols, Sterile Solutions/Injectables, Solid Dose, Formulation Services, Analytical Development Validation, Stability Services, Regulatory Support and Integrated Project Management.
Read More Inyx Inc (IYXI) Chart
Financial Metrics & Statements of Inyx Inc (IYXI)
FAQ's for Inyx Inc (IYXI)
- According to Musaffa’s Shariah screening methodology, Inyx Inc (IYXI) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.